Cargando…

Epstein-Barr–negative MS: a true phenomenon?

Detalles Bibliográficos
Autores principales:	Dobson, Ruth, Kuhle, Jens, Middeldorp, Jaap, Giovannoni, Gavin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Clinical/Scientific Notes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292929/ https://www.ncbi.nlm.nih.gov/pubmed/28203615 http://dx.doi.org/10.1212/NXI.0000000000000318

Ejemplares similares

Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom
por: Kuri, Ashvin, et al.
Publicado: (2020)

Systematic review and meta-analysis of the association between Epstein–Barr virus, multiple sclerosis and other risk factors
por: Jacobs, Benjamin M, et al.
Publicado: (2020)

Viral pathophysiology of multiple sclerosis: A role for Epstein-Barr virus infection?
por: Maghzi, Amir-Hadi, et al.
Publicado: (2011)

Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy
por: Rust, Heiko, et al.
Publicado: (2016)

Varicella-zoster virus encephalitis mimicking toxoplasmosis relapse
por: Marques, Inês Brás, et al.
Publicado: (2015)

Therapeutic implications of Epstein–Barr virus infection for the treatment of nasopharyngeal carcinoma
por: Hutajulu, Susanna Hilda, et al.
Publicado: (2014)

Assessment of biomedical engineering knowledge using true–false questions
por: Sreenivasa, Manish, et al.
Publicado: (2022)

Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML
por: Fischer-Barnicol, Bettina, et al.
Publicado: (2020)

Cumulative Roles for Epstein-Barr Virus, Human Endogenous Retroviruses, and Human Herpes Virus-6 in Driving an Inflammatory Cascade Underlying MS Pathogenesis
por: Meier, Ute-Christiane, et al.
Publicado: (2021)

Guillain-Barré syndrome related to COVID-19 infection
por: Alberti, Paola, et al.
Publicado: (2020)

High proportion of Guillain-Barré syndrome associated with chikungunya in Northeast Brazil
por: Matos, Aline de Moura Brasil, et al.
Publicado: (2020)

Guillain-Barré syndrome related to SARS-CoV-2 infection
por: Bigaut, Kévin, et al.
Publicado: (2020)

Presence of SARS-CoV-2 Transcripts in the Choroid Plexus of MS and Non-MS Patients With COVID-19
por: Fuchs, Vidmante, et al.
Publicado: (2021)

Endocarditis following ocrelizumab in relapsing-remitting MS
por: Faissner, Simon, et al.
Publicado: (2020)

Telomerase Activity Impacts on Epstein-Barr Virus Infection of AGS Cells
por: Rac, Jürgen, et al.
Publicado: (2015)

Longitudinally extensive myelitis in MS mimicking neuromyelitis optica
por: Whittam, Daniel, et al.
Publicado: (2017)

Intracerebral lymphoproliferative disorder in an MS patient treated with fingolimod
por: de Jong, Brigit A., et al.
Publicado: (2018)

Case of alemtuzumab-related alopecia areata management in MS
por: Chan, Jillian K., et al.
Publicado: (2018)

Acute liver injury in a Glatopa-treated patient with MS
por: Sabatino, Joseph J., et al.
Publicado: (2017)

Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab
por: Moreira Ferreira, Vanessa F., et al.
Publicado: (2019)

Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients
por: van der Zwan, Marieke, et al.
Publicado: (2020)

Dramatic rebounds of MS during pregnancy following fingolimod withdrawal
por: Novi, Giovanni, et al.
Publicado: (2017)

Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS
por: Sauer, Eva-Maria, et al.
Publicado: (2018)

COVID-19 in MS: Initial observations from the Pacific Northwest
por: Bowen, James D., et al.
Publicado: (2020)

Epstein-Barr virus infection presenting as encephalitis in HIV—Phenomenon not seen frequently
por: Mahajan, Rahul, et al.
Publicado: (2022)

Epstein-Barr Virus Gastritis
por: Oki, Masayuki, et al.
Publicado: (2017)

A fatal case of daclizumab-induced liver failure in a patient with MS
por: Stettner, Mark, et al.
Publicado: (2019)

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS
por: Hodecker, Sibylle C., et al.
Publicado: (2017)

Lipoic Acid Pharmacokinetics at Baseline and 1 year in Secondary Progressive MS
por: Bittner, Frank, et al.
Publicado: (2017)

Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy in MS
por: Scheibe, Franziska, et al.
Publicado: (2018)

HSV-2–related hemophagocytic lymphohistiocytosis in a fingolimod-treated patient with MS
por: Ikumi, Kazuhiro, et al.
Publicado: (2016)

VZV-associated acute retinal necrosis in a patient with MS treated with natalizumab
por: Pawlitzki, Marc, et al.
Publicado: (2018)

Tumefactive demyelination with a transient appearance of oligoclonal bands in MS under fingolimod
por: Okada, Kazumasa, et al.
Publicado: (2018)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

BamHI-A rightward frame 1, an Epstein–Barr virus-encoded oncogene and immune modulator
por: Hoebe, Eveline K, et al.
Publicado: (2013)

IgA autoantibodies against native myelin basic protein in a patient with MS
por: Schumacher, Heike, et al.
Publicado: (2019)

Epstein–Barr Virus and Multiple Sclerosis: Wrong Place, Wrong Time?
por: Maghzi, Amir-Hadi, et al.
Publicado: (2011)

Treatment-resistant immune thrombocytopenic purpura associated with LDN use in a patient with MS
por: Torkildsen, Øivind, et al.
Publicado: (2014)

pRNFL as a marker of disability worsening in the medium/long term in patients with MS
por: Cordano, Christian, et al.
Publicado: (2018)

Evolution of functional antibodies following acute Epstein-Barr virus infection
por: Karsten, Christina B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_efs2nrn946o40fb39d1gehc8m2